Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

NCT05112159 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: IPG1094 300 mg SAD
DRUG: IPG1094 600 mg SAD
DRUG: IPG1094 900 mg SAD
DRUG: IPG1094 1200 mg SAD
DRUG: IPG1094 600 mg MAD QD
DRUG: IPG1094 200 mg MAD BID
DRUG: IPG1094 300 mg MAD BID
DRUG: IPG1094 300 mg Fed-Fasted
DRUG: IPG1094 300 mg Fasted-Fed
DRUG: IPG1094 100 mg SAD

Sponsor

Nanjing Immunophage Biotech Co., Ltd